Ambalal Sarabhai Enterprises Ltd. benchmarking: Perfomance to industry peers

Financial

	Ambalal Sarabhai Ent	Brooks Laboratories	Lyka Labs
Operational Metrics
Pharmaceuticals
R&D as a % of Total Sales	0.01 %	n/a	n/a
Financials
5 yr Average ROE	19.11 %	-21.13 %	62.44 %
5yr average Equity Multiplier	2.07	1.68	2.9
5yr Average Asset Turnover Ratio	0.75	0.62	0.73
5yr Avg Net Profit Margin	10.89 %	-21.45 %	-0.79 %
Price to Book	1.48	1.8	2.66
P/E	22.71	18.07	131.06
5yr Avg Cash Conversion Cycle	-37.53 Days	23.75 Days	32.55 Days
Inventory Days	33.51 Days	83.11 Days	24.2 Days
Days Receivable	63.69 Days	80.26 Days	92.33 Days
Days Payable	147.98 Days	163.46 Days	106.74 Days
5yr Average Interest Coverage Ratio	9.88	-11.18	2.2
5yr Avg ROCE	24.01 %	-11.18 %	25.83 %
5yr Avg Operating Profit Margin	5.29 %	-10.26 %	24.02 %
5 yr average Debt to Equity	0.32	0.18	1.25
5yr CAGR Net Profit	-30.01 %	-12.45 %	n/a
5yr Average Return on Assets	8.69 %	-13.31 %	1.72 %
Shareholdings
Promoter Holding	31.35 %	52.62 %	58.16 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.59 %	-13.79 %	10.57 %
Change in Mutual Fund Holding (3 Yrs)	0.0	9.9 %	-3.53 %

	Ambalal Sarabhai Ent	Brooks Laboratories	Lyka Labs
Product Wise Break-Up	Product Wise Break-Up Pharmaceutical 58.53 Electronics 41.47 Formulations 0 Bulk Drugs 0	Product Wise Break-Up Formulations 0 Electronics 0 Pharmaceutical 0 Bulk Drugs 0 Others 100	Product Wise Break-Up Formulations 96.8 Electronics 0 Pharmaceutical 0 Bulk Drugs 3.2
Location Wise Break-Up	Location Wise Break-Up India 64.56 Rest of the World 35.44 International 0 Domestic 0	-	Location Wise Break-Up India 63.48 India 0 Rest of the World 0 International 36.52
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 93.71 Electronics 6.29	-	-
Capex	Capex Pharmaceuticals 57.12 Electronics 42.88	-	-
Asset Break-Up	Asset Break-Up Pharmaceuticals 77.67 Electronics 22.33	-	-